BIOA
BioAge Labs, Inc.
Next earnings Aug 4, 2026 · consensus $-0.62 EPS, $1.92M rev
Last earnings +1.0% on 2026-05-08
$23.76
▲ +5.04%$23.76▲ +447.47%
over 1Y
L $4.12EODHDH $23.76
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.0%
1W+10.7%
1M+40.2%
3M+47.1%
YTD+85.2%
1Y+447.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 15 analysts
Buy
Clinical-stage biotech with one Phase 1 asset, $189M cash burning at ~$82M/yr, and a $1.01B market cap pricing in success not yet earned.
Revenue $8.99M · FY2025
BioAge Labs is a pre-revenue clinical-stage biopharmaceutical company whose entire equity story rests on BGE-102, a novel oral NLRP3 inhibitor that only entered Phase 1 SAD/MAD dosing in late 2025. The FY2025 financials confirm the binary nature of the bet: $8.99M of revenue (almost certainly collaboration/grant income, not product sales) against a $80.6M net loss, a -$92.8M operating loss, and -$81.6M of operating cash burn that worsened 58.4% year-over-year. R&D rose 25.3% to $74.0M, which is the right direction for a developmental biotech but accelerates the cash drain.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | $0.00 | $8.99M |
| Gross profit | — | — | — |
| Operating income | -$48.4M | -$78.2M | -$92.8M |
| Net income | -$63.9M | -$71.1M | -$80.6M |
| Diluted EPS | -$38.17 | -$6.63 | -$2.24 |
| Net margin | — | — | -896.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$868M
EV / EBITDA—
EV / Sales96.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-7.6%
FCF yield-7.8%
Quality & risk
ROIC (est.)-26.7%
Free cash flow-$82.3M
Total debt$2.65M
Net cash$186M
Altman Z-Score26.20 safe
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+23.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
- 8-K Shareholder vote2026-06-12
Annual meeting vote results disclosed; routine governance, no business impact.
- 8-K Earnings results2026-05-08
Q1 2026 10-Q; continued R&D-heavy burn against BGE-102 development timeline.
- 10-Q Quarterly report2026-05-08
Q1 2026 10-Q; continued R&D-heavy burn against BGE-102 development timeline.
- DEF 14A Proxy statement2026-04-21
DEF 14A proxy: routine board/say-on-pay items ahead of annual meeting.
- 8-K Earnings results2026-03-24
FY2025 10-K: BGE-102 lead program; loss -$80.6M, R&D +25%, cash runway shortening.
- 10-K Annual report2026-03-24
FY2025 10-K: BGE-102 lead program; loss -$80.6M, R&D +25%, cash runway shortening.
- 8-K Material agreement2026-01-22
Entered material definitive agreement; potential partnership or financing arrangement.
- 8-K Reg FD disclosure2026-01-20
Reg FD update, likely follow-on BGE-102 Phase 1 commentary post-MAD data.
- 8-K Reg FD disclosure2026-01-12
BGE-102 Phase 1 SAD/MAD readout: well-tolerated, supports once-daily oral dosing.
Recent filings
all on EDGAR ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-06-102026-06-12open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-082026-05-08open ↗10-QPeriod ending 2026-03-312026-05-08open ↗SCHEDULE 13GFiling2026-04-27open ↗
Frequently asked
- Is BioAge Labs, Inc. (BIOA) a buy?
- BIOA currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Clinical-stage biotech with one Phase 1 asset, $189M cash burning at ~$82M/yr, and a $1.01B market cap pricing in success not yet earned.
- What is BioAge Labs, Inc.'s quality score?
- BIOA scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001709941, latest 10-Q filed 2026-05-08) · EODHD · analysis by claude-code · as of 6/25/2026, 2:25:12 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.